This webinar first aired on Tuesday, May 5, 2020

Webinar Objectives

  • Describe 2 – 3 data points about the current state of COVID-19
  • Identify 4 lessons learned from the COVID-19 outbreak
  • Discuss 3 of the benefits of using telehealth in asthma care


Dr. Purvi Purikh and Dr. Jackie Eghrari-Sabet will join Allergy & Asthma Network President & CEO Tonya Winders to mark World Asthma Day with a program that will look at the latest information on COVID-19, telehealth, digital health and the COVID-19 registry as we explore the impact on the healthcare system and respiratory patients.



Questions and Answers from the Webinar

If a person with asthma contracts COVID-19, do symptoms mirror that of someone who doesn’t have asthma? Are there specific red flags a person with asthma should watch for?

It is not yet known if non-asthma patients with COVID-19 have similar symptoms as asthma patients with COVID-19. People with asthma are higher risk for complications from COVID-19.

Two of the main presenting symptoms of COVID-19 are cough and shortness of breath, but those are also common presentations of worsening asthma. For this reason, it is crucial to maintain good asthma control.

COVID-19 also often comes with fever, body aches, loss of taste or smell, which does help distinguish it from worsening asthma.

What is the reason for increased hospitalizations of people with asthma in the 18-49 age range?

It is not known at this time, but more data in the coming months may provide answers. There have been other viruses such as versions of influenza or swine flu that affected different age groups. With regards to this group of asthmatics between the ages of 18-49, many were diagnosed in childhood. One idea is that due to living with asthma for many years, the long-term impact on the lungs may make this group particularly vulnerable.  For this reason, it is crucial for those living with asthma to make sure that it is well controlled

What are considerations for administering nebulizer treatments (such as albuterol) in a childcare or school setting? What is the risk of transmission of COVID-19 through nebulizer treatments?

The current data suggests avoiding nebulizer treatments in public settings as that can nebulize the virus. Data suggests the virus can stay in the air for several hours. In most clinical settings, nebulizers are no longer used and, if a patient needs albuterol, it would be through an MDI.

Also, albuterol is a quick-relief medication, and if it is administered in a childcare or school setting, that is an indication the child may have poor asthma control.

Where can sublingual immunotherapy be purchased?

A prescription must be obtained from a doctor and then filled through the route any other prescription is filled – a retail pharmacy or a mail-order pharmacy.

With Xolair treatment, how is that being obtained for home use?

Xolair is not an approved home treatment in the United States.

We’re here to help!  The Allergy & Asthma Network is committed to getting information into the hands of our patients and stakeholders during this uncertain time of the COVID-19 crisis.